Economic Burden of Overweight and Obesity in Sweden: Current Estimates and Future Projections
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Adam Fridhammar und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Swedish Institute for Health Economics, Lund, Sweden. Hauptthemen laut MEDLINE: Cost of Illness, Obesity, Health Care Costs, Overweight. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Scandinavia AB, Swedish Foundation for Strategic Research.
Abstract (Originalsprache)
Aims
Overweight and obesity are major public health challenges and well‐established risk factors for cardiovascular disease, cancer and premature mortality. We estimated the economic burden of overweight and obesity in Sweden in 2023 and projected the future economic burden in 2040 under alternative scenarios of increasing prevalence. Materials and Methods A prevalence‐based cost‐of‐illness approach was used to estimate the economic burden of overweight and obesity in Sweden in 2023 from a societal perspective, including healthcare, social services, pharmaceuticals, productivity losses and informal care. The population attributable fraction method was used to estimate the additional cost burden from overweight and obesity compared to normal weight.
Results
The total economic burden was estimated at approximately EUR 7 billion (EUR 664 per capita), with EUR 2.6 billion from overweight and EUR 4.4 billion from obesity. Productivity losses accounted for 71% of total costs, healthcare costs 21% and pharmaceuticals, informal care and social services 8%. Projections to 2040 suggest that demographic changes alone could increase the burden to EUR 7.2 billion, while rising prevalence could raise it to EUR 8.6 billion. A decrease of one percentage point in obesity prevalence would counteract the demographic effects, resulting in a reduction to EUR 7.1 billion in the projection to 2040.
Conclusions
The findings highlight the urgent need for effective obesity interventions. Societal strategies promoting healthy lifestyles, targeted prevention and improved access to obesity surgery and evidence‐based treatments may reduce the rising prevalence of obesity. Policymakers should weigh short‐term costs against long‐term savings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Swedish Institute for Health Economics, Lund, Sweden.
- Department of Paediatrics, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Region Västra Götaland, Queen Silvia Children's Hospital, Gothenburg, Sweden.
- Department of Internal Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Novo Nordisk Scandinavia AB, Malmö, Sweden.
- Department of Clinical Sciences, Lund University, Malmö, Sweden.
ORCID-Profile: Adam Fridhammar, Jovanna Dahlgren, Marije Galavazi, Lena Hjelm, Jonatan Dereke, Katarina Steen Carlsson
Förderung
- Novo Nordisk Scandinavia AB
- Swedish Foundation for Strategic Research
Zitieren
APA
Fridhammar, A., Dahlgren, J., Galavazi, M., Hjelm, L., Dereke, J., & Carlsson, K. S. (2026). Economic Burden of Overweight and Obesity in Sweden: Current Estimates and Future Projections. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71122
Vancouver
Fridhammar A, Dahlgren J, Galavazi M, Hjelm L, Dereke J, Carlsson KS. Economic Burden of Overweight and Obesity in Sweden: Current Estimates and Future Projections. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71122
BibTeX
@article{Fridhammar2026,
author = {Fridhammar, Adam and Dahlgren, Jovanna and Galavazi, Marije and Hjelm, Lena and Dereke, Jonatan and Carlsson, Katarina Steen},
title = {Economic Burden of Overweight and Obesity in Sweden: Current Estimates and Future Projections},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71122}
}
EUVIMED